{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:23:20Z","timestamp":1792513400101,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Yellow fever\u2013associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patient and methods<\/jats:title>\n                  <jats:p>Here we describe clinical and virological response to use of off-licence sofosbuvir as post-exposure prophylaxis for a patient inadvertently given yellow fever vaccine despite previous thymectomy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A 14-day course of oral sofosbuvir was administered in an outpatient setting with regular clinical and biochemical monitoring. The patient remained well without developing clinical features of YEL-AVD and did not experience adverse effects from the treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This supports the use of sofosbuvir as post-exposure prophylaxis in patients at high risk of developing YEL-AVD. Ongoing trials of efficacy of sofosbuvir in yellow fever infection may result in stronger support for this approach in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae484","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T12:22:34Z","timestamp":1737116554000},"page":"825-827","source":"Crossref","is-referenced-by-count":4,"title":["Sofosbuvir as post-exposure prophylaxis for yellow fever\u2013associated viscerotropic disease (YEL-AVD)"],"prefix":"10.1093","volume":"80","author":[{"given":"Jessica","family":"Barrett","sequence":"first","affiliation":[{"name":"Department of Infection, North Bristol NHS Trust , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Mutengesa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Warrell","sequence":"additional","affiliation":[{"name":"Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down , Salisbury ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Rampling","sequence":"additional","affiliation":[{"name":"Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down , Salisbury ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Owen","sequence":"additional","affiliation":[{"name":"Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down , Salisbury ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Patel","sequence":"additional","affiliation":[{"name":"National Travel Health Network and Centre (NaTHNaC), UCLH NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-4337","authenticated-orcid":false,"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Moores","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Scobie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Free London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"2025061212363191800_dkae484-B1","doi-asserted-by":"publisher","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"2025061212363191800_dkae484-B2","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"2025061212363191800_dkae484-B3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.vaccine.2004.01.026","article-title":"Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX","volume":"22","author":"Kitchener","year":"2004","journal-title":"Vaccine"},{"key":"2025061212363191800_dkae484-B4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","article-title":"History of thymoma and yellow fever vaccination","volume":"364","author":"Barwick Eidex","year":"2004","journal-title":"Lancet"},{"key":"2025061212363191800_dkae484-B5","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"2025061212363191800_dkae484-B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4269\/ajtmh.13-0542","article-title":"Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data","volume":"90","author":"Seligman","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2025061212363191800_dkae484-B7"},{"key":"2025061212363191800_dkae484-B8","doi-asserted-by":"publisher","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"2025061212363191800_dkae484-B9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1128\/CVI.00369-09","article-title":"Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination","volume":"17","author":"Silva","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2025061212363191800_dkae484-B10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/jtm.12135","article-title":"A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands","volume":"21","author":"van de Pol","year":"2014","journal-title":"J Travel Med"},{"key":"2025061212363191800_dkae484-B11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.aohep.2019.09.001","article-title":"Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure","volume":"18","author":"Mendes","year":"2019","journal-title":"Ann Hepatol"},{"key":"2025061212363191800_dkae484-B12","doi-asserted-by":"publisher","first-page":"e0007072","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","volume":"13","author":"de Freitas","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2025061212363191800_dkae484-B13","doi-asserted-by":"publisher","first-page":"ofae312","DOI":"10.1093\/ofid\/ofae312","article-title":"Sofosbuvir off-label treatment of yellow fever patients during an outbreak in Brazil, 2018: a cohort study","volume":"11","author":"Rezende","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025061212363191800_dkae484-B14","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025061212363191800_dkae484-B15","doi-asserted-by":"publisher","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antiviral Res"},{"key":"2025061212363191800_dkae484-B16","volume-title":"Clinical Management of Yellow Fever in the Region of the Americas. Experiences and Recommendations for Health Services","author":"Pan American Health Organisation","year":"2023"},{"key":"2025061212363191800_dkae484-B17","doi-asserted-by":"publisher","first-page":"e027207","DOI":"10.1136\/bmjopen-2018-027207","article-title":"Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)","volume":"9","author":"Figueiredo-Mello","year":"2019","journal-title":"BMJ Open"},{"key":"2025061212363191800_dkae484-B18","doi-asserted-by":"publisher","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/825\/61481960\/dkae484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/825\/61481960\/dkae484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T16:36:41Z","timestamp":1749746201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/825\/7959368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae484","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,17]]}}}